Browsing Category
Pharma Industry News
4764 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Laurus Labs financial overview: Q2 and H1 FY24 revenue and earnings insights
Laurus Labs Ltd., a prominent pharmaceutical and biotech R&D entity in India, has released its H1 FY24 financial…
FDA approves Zydus Lifesciences’ ZITUVIO tablets for Type 2 diabetes
Zydus Lifesciences Limited announced today that the U.S. Food and Drug Administration (FDA) has granted approval for its…
Rossari Biotech Q2 FY24 results: Record performance with increased revenue and profit
Rossari Biotech, an India-based Speciality-Chemicals manufacturer, showcased a remarkable Q2 FY24 performance with revenue from operations reaching Rs.…
Zydus Lifesciences announces Punit Patel as new CEO for Americas operations
Global lifesciences firm, Zydus Lifesciences Limited, recently declared the appointment of Punit Patel as the President and Chief…
PTC Therapeutics collaborates with Royalty Pharma in $1.5bn Evrysdi royalty agreement
PTC Therapeutics, Inc. (NASDAQ: PTCT) has forged an agreement with Royalty Pharma plc., monetizing up to a staggering…
RPG Life Sciences announces Q2 FY24 financial results with significant growth
RPG Life Sciences Limited, a leading name in pharmaceutical products manufacturing and marketing, has unveiled its financial results…
Glenmark Pharmaceuticals secures FDA approval for generic version of Otezla Tablets
Glenmark Pharmaceuticals Ltd. has successfully secured the final approval from the United States Food & Drug Administration (U.S.…
Incyte’s Ruxolitinib Cream demonstrates promising efficacy in TRuE-AD3 study
Incyte (Nasdaq:INCY), an esteemed biopharmaceutical giant, has unveiled compelling expanded findings from its Phase 3 TRuE-AD3 study on…
Ankyra Therapeutics’ cANK-101 delivers promising preliminary data in canine melanoma trial
Ankyra Therapeutics, a biotech innovator, unveiled groundbreaking preliminary results from their exploratory Phase 1 canine clinical trial today.…
Eli Lilly’s mirikizumab triumphs in Phase 3 Crohn’s disease study
Eli Lilly and Company (NYSE: LLY), a pharmaceutical leader, unveiled that mirikizumab, its cutting-edge interleukin-23p19 antagonist, has demonstrated…